Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome

OBJECTIVE: To evaluate the safety and preliminary pharmacokinetics of a pharmaceutical formulation of purified cannabidiol (CBD) in children with Dravet syndrome. METHODS: Patients aged 4–10 years were randomized 4:1 to CBD (5, 10, or 20 mg/kg/d) or placebo taken twice daily. The double-blind trial...

Descripción completa

Detalles Bibliográficos
Autores principales: Devinsky, Orrin, Patel, Anup D., Thiele, Elizabeth A., Wong, Matthew H., Appleton, Richard, Harden, Cynthia L., Greenwood, Sam, Morrison, Gilmour, Sommerville, Kenneth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5890607/
https://www.ncbi.nlm.nih.gov/pubmed/29540584
http://dx.doi.org/10.1212/WNL.0000000000005254

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5890607/
https://www.ncbi.nlm.nih.gov/pubmed/29540584
http://dx.doi.org/10.1212/WNL.0000000000005254

Ejemplares similares